ARTICLE | Management Tracks
Sandoz’ Francis to take the helm at Teva
Plus: Devey becomes CMO at Quell, and updates from Diadem, Pfizer and more
November 21, 2022 10:58 PM UTC
Richard Francis will become president and CEO at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) on Jan. 1, 2023, succeeding Kåre Schultz, who is retiring. Francis is CEO at Purespring Therapeutics Ltd. and Forcefield Therapeutics Ltd., both portfolio companies of Syncona Ltd. (LSE:SYNC), where he is an operating partner. He was previously CEO at Sandoz Ltd. for five years, before which he held roles of increasing responsibilities at Biogen Inc. (NASDAQ:BIIB) over 12 years.
Another Syncona-backed company, Quell Therapeutics Ltd., hired Luke Devey as CMO. Devey was VP and head of translational science at Janssen Pharmaceuticals. Quell is developing regulatory T cell therapies...